Nasdaq · CIK 0001133869
CAPR CAPRICOR THERAPEUTICS, INC.
Insider trading from SEC Form 4. Last filing Mar 27, 2026.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at CAPRICOR THERAPEUTICS, INC., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 68 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 30, 2025 | Karen Krasney EVP, GENERAL COUNSEL | MOption exercise Common Stock | +2,500 | $1.39 | $3,475 | 30,547 | Mar 27, 2026 |
| Dec 30, 2025 | Karen Krasney EVP, GENERAL COUNSEL | MOption exercise Stock Option (Right to Buy)derivative | -2,500 | $0.00 | $0 | 0 | Mar 27, 2026 |
| Jan 5, 2026 | Paul Gisbert Auwaerter director | AGrant or award Stock Option (Right to Buy)derivative | +15,500 | $0.00 | $0 | 15,500 | Jan 7, 2026 |
| Jan 5, 2026 | Anthony Bergmann CHIEF FINANCIAL OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jan 7, 2026 |
| Jan 5, 2026 | Mike Kelliher director | AGrant or award Stock Option (Right to Buy)derivative | +15,500 | $0.00 | $0 | 15,500 | Jan 7, 2026 |
| Jan 5, 2026 | George W Dunbar Jr director | AGrant or award Stock Option (Right to Buy)derivative | +15,500 | $0.00 | $0 | 15,500 | Jan 7, 2026 |
| Jan 5, 2026 | David B Musket director | AGrant or award Stock Option (Right to Buy)derivative | +15,500 | $0.00 | $0 | 15,500 | Jan 7, 2026 |
| Jan 5, 2026 | Frank Litvack director | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jan 7, 2026 |
| Jan 5, 2026 | Linda Marban CHIEF EXECUTIVE OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jan 7, 2026 |
| Jan 5, 2026 | Philip J Gotwals director | AGrant or award Stock Option (Right to Buy)derivative | +15,500 | $0.00 | $0 | 15,500 | Jan 7, 2026 |
| Jan 5, 2026 | Karimah Es Sabar director | AGrant or award Stock Option (Right to Buy)derivative | +15,500 | $0.00 | $0 | 15,500 | Jan 7, 2026 |
| Jan 5, 2026 | Karen Krasney EVP, GENERAL COUNSEL | AGrant or award Stock Option (Right to Buy)derivative | +22,500 | $0.00 | $0 | 22,500 | Jan 7, 2026 |
| Jan 5, 2026 | Paul Gisbert Auwaerter director | AGrant or award Stock Option (Right to Buy)derivative | +1,360 | $0.00 | $0 | 1,360 | Jan 7, 2026 |
| Jan 5, 2026 | Karen Krasney EVP, GENERAL COUNSEL | AGrant or award Stock Option (Right to Buy)derivative | +22,500 | $0.00 | $0 | 22,500 | Jan 7, 2026 |
| Jan 5, 2026 | Linda Marban CHIEF EXECUTIVE OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jan 7, 2026 |
| Jan 5, 2026 | Anthony Bergmann CHIEF FINANCIAL OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jan 7, 2026 |
| Jan 5, 2026 | Linda Marban CHIEF EXECUTIVE OFFICER | AGrant or award Restricted Stock Unitsderivative | +7,500 | $0.00 | $0 | 7,500 | Jan 7, 2026 |
| Jan 5, 2026 | Anthony Bergmann CHIEF FINANCIAL OFFICER | AGrant or award Restricted Stock Unitsderivative | +2,500 | $0.00 | $0 | 2,500 | Jan 7, 2026 |
| Jan 5, 2026 | Paul Gisbert Auwaerter director | AGrant or award Stock Option (Right to Buy)derivative | +5,420 | $0.00 | $0 | 5,420 | Jan 7, 2026 |
| Dec 19, 2025 | George W Dunbar Jr director | MOption exercise Common Stock | +3,000 | $1.39 | $4,170 | 14,306 | Dec 23, 2025 |
| Dec 19, 2025 | George W Dunbar Jr director | MOption exercise Stock Option (Right to Buy)derivative | -3,000 | $0.00 | $0 | 0 | Dec 23, 2025 |
| Mar 3, 2025 | Linda Marban CHIEF EXECUTIVE OFFICER | MOption exercise Common Stock | +25,000 | $1.39 | $35k | 223,604 | Mar 5, 2025 |
| Mar 5, 2025 | Linda Marban CHIEF EXECUTIVE OFFICER | JOther Common Stock | -12,500 | $0.00 | $0 | 211,104 | Mar 5, 2025 |
| Mar 3, 2025 | Linda Marban CHIEF EXECUTIVE OFFICER | MOption exercise Stock Option (Right to Buy)derivative | -25,000 | $0.00 | $0 | 0 | Mar 5, 2025 |
| Mar 3, 2025 | George W Dunbar Jr director | MOption exercise Common Stock | +750 | $1.39 | $1,043 | 11,306 | Mar 4, 2025 |
| Mar 3, 2025 | Frank Litvack director | MOption exercise Common Stock | +25,000 | $1.39 | $35k | 132,382 | Mar 4, 2025 |
| Mar 3, 2025 | Anthony Bergmann CHIEF FINANCIAL OFFICER | MOption exercise Common Stock | +2,500 | $1.39 | $3,475 | 8,223 | Mar 4, 2025 |
| Mar 3, 2025 | Frank Litvack director | FTax withholding Common Stock | -2,543 | $13.67 | $35k | 129,839 | Mar 4, 2025 |
| Mar 3, 2025 | George W Dunbar Jr director | MOption exercise Stock Option (Right to Buy)derivative | -750 | $0.00 | $0 | 0 | Mar 4, 2025 |
| Mar 3, 2025 | Anthony Bergmann CHIEF FINANCIAL OFFICER | MOption exercise Stock Option (Right to Buy)derivative | -2,500 | $0.00 | $0 | 0 | Mar 4, 2025 |
| Mar 3, 2025 | Frank Litvack director | MOption exercise Stock Option (Right to Buy)derivative | -25,000 | $0.00 | $0 | 0 | Mar 4, 2025 |
| Feb 27, 2025 | Earl M Collier Jr director | MOption exercise Common Stock | +750 | $1.39 | $1,043 | 57,606 | Feb 28, 2025 |
| Feb 27, 2025 | Earl M Collier Jr director | MOption exercise Stock Option (Right to Buy)derivative | -750 | $0.00 | $0 | 0 | Feb 28, 2025 |
| Jan 2, 2025 | David B Musket director | AGrant or award Stock Option (Right to Buy)derivative | +11,940 | $0.00 | $0 | 11,940 | Jan 6, 2025 |
| Jan 2, 2025 | George W Dunbar Jr director | AGrant or award Stock Option (Right to Buy)derivative | +11,940 | $0.00 | $0 | 11,940 | Jan 6, 2025 |
| Jan 2, 2025 | Karimah Es Sabar director | AGrant or award Stock Option (Right to Buy)derivative | +11,940 | $0.00 | $0 | 11,940 | Jan 6, 2025 |
| Jan 2, 2025 | Earl M Collier Jr director | AGrant or award Stock Option (Right to Buy)derivative | +11,940 | $0.00 | $0 | 11,940 | Jan 6, 2025 |
| Jan 2, 2025 | Mike Kelliher director | AGrant or award Stock Option (Right to Buy)derivative | +11,940 | $0.00 | $0 | 11,940 | Jan 6, 2025 |
| Jan 2, 2025 | Philip J Gotwals director | AGrant or award Stock Option (Right to Buy)derivative | +11,940 | $0.00 | $0 | 11,940 | Jan 6, 2025 |
| Jan 2, 2025 | Linda Marban CHIEF EXECUTIVE OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +210,000 | $0.00 | $0 | 210,000 | Jan 6, 2025 |
| Jan 2, 2025 | Anthony Bergmann CHIEF FINANCIAL OFFICER | AGrant or award Common Stock | +3,342 | $0.00 | $0 | 5,723 | Jan 6, 2025 |
| Jan 2, 2025 | Karen Krasney EVP, GENERAL COUNSEL | AGrant or award Stock Option (Right to Buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Jan 6, 2025 |
| Jan 2, 2025 | Paul Gisbert Auwaerter director | AGrant or award Stock Option (Right to Buy)derivative | +11,940 | $0.00 | $0 | 11,940 | Jan 6, 2025 |
| Jan 2, 2025 | Mike Kelliher director | AGrant or award Stock Option (Right to Buy)derivative | +1,440 | $0.00 | $0 | 1,440 | Jan 6, 2025 |
| Jan 2, 2025 | Linda Marban CHIEF EXECUTIVE OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +34,962 | $0.00 | $0 | 34,962 | Jan 6, 2025 |
| Jan 2, 2025 | Karimah Es Sabar director | AGrant or award Stock Option (Right to Buy)derivative | +2,520 | $0.00 | $0 | 2,520 | Jan 6, 2025 |
| Jan 2, 2025 | David B Musket director | AGrant or award Stock Option (Right to Buy)derivative | +6,480 | $0.00 | $0 | 6,480 | Jan 6, 2025 |
| Jan 2, 2025 | Paul Gisbert Auwaerter director | AGrant or award Stock Option (Right to Buy)derivative | +1,440 | $0.00 | $0 | 1,440 | Jan 6, 2025 |
| Jan 2, 2025 | George W Dunbar Jr director | AGrant or award Stock Option (Right to Buy)derivative | +3,600 | $0.00 | $0 | 3,600 | Jan 6, 2025 |
| Jan 2, 2025 | Anthony Bergmann CHIEF FINANCIAL OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Jan 6, 2025 |
| Jan 2, 2025 | Philip J Gotwals director | AGrant or award Stock Option (Right to Buy)derivative | +2,160 | $0.00 | $0 | 2,160 | Jan 6, 2025 |
| Jan 2, 2025 | Earl M Collier Jr director | AGrant or award Stock Option (Right to Buy)derivative | +3,240 | $0.00 | $0 | 3,240 | Jan 6, 2025 |
| Jan 2, 2025 | Earl M Collier Jr director | AGrant or award Stock Option (Right to Buy)derivative | +5,750 | $0.00 | $0 | 5,750 | Jan 6, 2025 |
| Jan 2, 2025 | Karimah Es Sabar director | AGrant or award Stock Option (Right to Buy)derivative | +5,750 | $0.00 | $0 | 5,750 | Jan 6, 2025 |
| Jan 2, 2025 | Philip J Gotwals director | AGrant or award Stock Option (Right to Buy)derivative | +5,750 | $0.00 | $0 | 5,750 | Jan 6, 2025 |
| Jan 2, 2025 | David B Musket director | AGrant or award Stock Option (Right to Buy)derivative | +5,750 | $0.00 | $0 | 5,750 | Jan 6, 2025 |
| Jan 2, 2025 | Mike Kelliher director | AGrant or award Stock Option (Right to Buy)derivative | +5,750 | $0.00 | $0 | 5,750 | Jan 6, 2025 |
| Jan 2, 2025 | Anthony Bergmann CHIEF FINANCIAL OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +6,170 | $0.00 | $0 | 6,170 | Jan 6, 2025 |
| Jan 2, 2025 | George W Dunbar Jr director | AGrant or award Stock Option (Right to Buy)derivative | +5,750 | $0.00 | $0 | 5,750 | Jan 6, 2025 |
| Jan 2, 2025 | Paul Gisbert Auwaerter director | AGrant or award Stock Option (Right to Buy)derivative | +5,750 | $0.00 | $0 | 5,750 | Jan 6, 2025 |
| Jan 2, 2025 | Frank Litvack director | AGrant or award Stock Option (Right to Buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Jan 6, 2025 |
| Dec 13, 2024 | Karen Krasney EVP, GENERAL COUNSEL | MOption exercise Common Stock | +8,000 | $1.39 | $11k | 28,047 | Dec 16, 2024 |
| Dec 13, 2024 | Karen Krasney EVP, GENERAL COUNSEL | MOption exercise Stock Option (Right to Buy)derivative | -3,000 | $0.00 | $0 | 0 | Dec 16, 2024 |
| Dec 13, 2024 | Karen Krasney EVP, GENERAL COUNSEL | MOption exercise Stock Option (Right to Buy)derivative | -5,000 | $0.00 | $0 | 0 | Dec 16, 2024 |
| Dec 3, 2024 | Frank Litvack director | MOption exercise Common Stockindirect: Held in Family Trust | +20,391 | $1.10 | $22k | 46,278 | Dec 4, 2024 |
| Dec 2, 2024 | Frank Litvack director | GGift Warrants (Right to Buy)derivative | -20,391 | $0.00 | $0 | 0 | Dec 4, 2024 |
| Dec 2, 2024 | Frank Litvack director | GGift Warrants (Right to Buy)derivativeindirect: Held by Family Trust | +20,391 | $0.00 | $0 | 20,391 | Dec 4, 2024 |
| Dec 3, 2024 | Frank Litvack director | MOption exercise Warrants (Right to Buy)derivativeindirect: Held by Family Trust | -20,391 | $0.00 | $0 | 0 | Dec 4, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Paul Gisbert Auwaerterdirector
- Anthony BergmannCHIEF FINANCIAL OFFICER
- Earl M Collier Jrdirector
- George W Dunbar Jrdirector
- Philip J Gotwalsdirector
- Mike Kelliherofficer, director
- Karen KrasneyEVP, GENERAL COUNSEL
- Frank Litvackdirector
- Linda MarbanCHIEF EXECUTIVE OFFICER
- David B Musketdirector
- Karimah Es Sabardirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.